Document is current
Any future updates will be listed below
-
Authors
Boccella, Nicola
Yu, GuoJun
Seaman, Steven https://orcid.org/0000-0003-3349-3334
Feng, Yang
Lee, Jaewon https://orcid.org/0000-0003-2267-6717
Tomassoni-Ardori, Francesco
Yang, Liping
Hsu, Kuo-Sheng
Dunleavey, James M.
Becker, Jodi
Hilton, Mary Beth
Morris, Karen
Borchin, Niza
So, Daeho
Bajgain, Pradip
Yanpallewar, Sudhirkumar
Gross, Ryan T. https://orcid.org/0000-0003-4849-0371
Dewan, Krish C.
Bowles, Dawn E.
Yuen, Darren A. https://orcid.org/0000-0002-0054-6607
Tessarollo, Lino https://orcid.org/0000-0001-6420-772X
St. Croix, Brad https://orcid.org/0000-0002-6246-0374
-
Funding
Funding for this research was provided by:
This work was supported by Center for Cancer Research (CCR), part of NCI’s intramural research program, NIH, Department of Health and Human Services (DHHS).
- License Information
-
More Information
Article History
Received: 29 July 2024
Accepted: 28 August 2025
First Online: 2 October 2025
Competing interests
: N.B., G.Y., J.M.D., L.T. and B.S.C. are NIH inventors of a provisional patent application (International application number PCT/US2025/017061) filed by the USA, as represented by the Secretary, Department of Health and Human Services, for the use of ANTXR1 antibodies for treatment of heart disease. The key finding, showing that anti-ANTXR1 antibodies can improve outcomes in heart disease, is revealed in the patent. B.S.C. is also an NIH inventor on a granted patent application (US application no. 9,181,340) filed by the USA, as represented by the Secretary, Department of Health and Human Services, that describes the initial development of the L2 anti-ANTXR1 antibody. This granted patent application does not cover specific aspects of this paper, such as the role of ANTXR1 in heart disease. The other authors declare no competing interests.
